

## Supplementary Figure Legends

**Supplementary Figure S1.** Ganetespib treatment overcomes the FGFR inhibitor resistant phenotype in FGFR3 mutant bladder cancer cell lines. FGFR3<sup>S249C</sup>-expressing 97-7 (*upper panel*) and FGFR3<sup>Y375C</sup>-expressing MGH-U3 (*lower panel*) cells were treated with increasing concentrations of ganetespib or BGJ398 and viability assessed after 72 hours.